BioSpace News Archive

Drug Development

Prometheus’ Anti-TL1A Monoclonal Antibody Notches Wins in Colitis, Crohn’s

Findings from the Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that Prometheus’ PRA023 is potentially safe and effective for treating ulcerative colitis and Crohn’s disease.

December 7, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Neurocrine’s $50M Neuro Asset Takes Strike Two

Neurocrine’s NBI-827104 failed to meet the primary endpoint in a Phase II study for epileptic encephalopathy with continuous spike-and-wave during sleep, the company announced Tuesday.

December 7, 2022
·
2 min read
·
Kate Goodwin
FDA

Pfizer Catches Up to GSK as RSV Candidate Snags Priority Review

In the heated race for a new respiratory syncytial virus vaccine for older adults, Pfizer gained ground on GSK after winning priority review designation for its vaccine candidate.

December 7, 2022
·
2 min read
·
Alex Keown
Drug Development

Lilly and Boehringer’s Jardiance Racks Up Another Type 2 Diabetes Win

Eli Lilly and Boehringer Ingelheim declared another victory Wednesday for Jardiance – this one for children and adolescents with Type 2 Diabetes.

December 7, 2022
·
2 min read
·
Heather McKenzie
Drug Development

AVROBIO Breaks Through in Severe Form of Gaucher Disease

AVROBIO is planning a Phase II/III registrational trial for its Gaucher Disease Type 3 (GD3) gene therapy candidate, AVR-RD-02, in 2023.

December 7, 2022
·
3 min read
·
Alex Keown
Business

Karuna Taps New CEO, Prepares to Submit NDA for Schizophrenia Candidate

Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul.

December 7, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Paragon Births Apogee to Address Unmet Need in Immunology/Inflammatory Space

Apogee Therapeutics sprang onto the immunology/inflammatory scene Wednesday heavy on capital but light on salient details of the pipeline.

December 7, 2022
·
2 min read
·
Heather McKenzie
Drug Development

Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

Novartis announced that its Kisqali with endocrine therapy offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer.

December 7, 2022
·
3 min read
·
Mark Terry
Business

Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2023

Kewaunee Scientific Corporation announced results for its second quarter ended October 31, 2022.

December 7, 2022
·
11 min read
Lone Star Bio

Caris Life Sciences to Present at the 2022 San Antonio Breast Cancer Symposium

Caris Life Sciences announced today that it will present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. SABCS is being held December 6-10, 2022 in San Antonio, Texas.

December 7, 2022
·
6 min read